tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

IMV Inc. to present initial patient data from VITALIZE trial

IMV Inc. announced initial patient data from the VITALIZE Phase 2B trial evaluating its lead DPX product, MVP-S, in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma who received at least three previous lines of treatment. Detailed results will be presented in a podium presentation at the Immuno-Oncology 360 degrees conference to be held in New York City on February 7-10, 2023.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on IMV:

Disclaimer & DisclosureReport an Issue

1